Prediction of One-Year Mortality Based upon A New Staged Mortality Risk Model in Patients with Aortic Stenosis Undergoing Transcatheter Valve Replacement.
TAVR
outcome
risk scores
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
08 Oct 2019
08 Oct 2019
Historique:
received:
25
08
2019
revised:
16
09
2019
accepted:
23
09
2019
entrez:
11
10
2019
pubmed:
11
10
2019
medline:
11
10
2019
Statut:
epublish
Résumé
In-depth knowledge about potential predictors of mortality in transcatheter aortic valve replacement (TAVR) is still warranted. Currently used risk stratification models for TAVR often fail to reach a holistic approach. We, therefore, aimed to create a new staged risk model for 1-year mortality including several new categories including (a) AS-entities (b) cardiopulmonary hemodynamics (c) comorbidities, and (d) different access routes. 737 transfemoral (TF) TAVR (84.3%) and 137 transapical (TA) TAVR (15.7%) patients were included. Predictors of 1-year mortality were assessed according to the aforementioned categories. Over-all 1-year mortality ( This new staged mortality risk model had incremental value for prediction of 1-year mortality after TAVR independently from the TAVR-era.
Sections du résumé
BACKGROUND
BACKGROUND
In-depth knowledge about potential predictors of mortality in transcatheter aortic valve replacement (TAVR) is still warranted. Currently used risk stratification models for TAVR often fail to reach a holistic approach. We, therefore, aimed to create a new staged risk model for 1-year mortality including several new categories including (a) AS-entities (b) cardiopulmonary hemodynamics (c) comorbidities, and (d) different access routes.
METHODS
METHODS
737 transfemoral (TF) TAVR (84.3%) and 137 transapical (TA) TAVR (15.7%) patients were included. Predictors of 1-year mortality were assessed according to the aforementioned categories.
RESULTS
RESULTS
Over-all 1-year mortality (
CONCLUSIONS
CONCLUSIONS
This new staged mortality risk model had incremental value for prediction of 1-year mortality after TAVR independently from the TAVR-era.
Identifiants
pubmed: 31597290
pii: jcm8101642
doi: 10.3390/jcm8101642
pmc: PMC6833068
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Am Coll Cardiol. 2018 Mar 27;71(12):1297-1308
pubmed: 29566812
J Heart Valve Dis. 2017 Jul;26(4):380-385
pubmed: 29302936
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Eur Heart J. 2017 Dec 1;38(45):3351-3358
pubmed: 29020232
Eur J Heart Fail. 2019 Feb;21(2):172-181
pubmed: 30328215
Int J Cardiol. 2018 Dec 1;272S:53-62
pubmed: 30527996
JACC Cardiovasc Interv. 2016 May 9;9(9):937-46
pubmed: 27085579
Cardiovasc Revasc Med. 2016 Jul-Aug;17(5):318-21
pubmed: 27394178
Circ Cardiovasc Interv. 2015 Jul;8(7):e002358
pubmed: 26156149
JACC Cardiovasc Interv. 2018 Sep 10;11(17):1746-1756
pubmed: 30190063
JACC Cardiovasc Interv. 2017 Dec 11;10(23):2414-2422
pubmed: 29217004
Circulation. 2017 Jun 20;135(25):e1159-e1195
pubmed: 28298458
Eur J Cardiothorac Surg. 2017 Oct 1;52(4):616-664
pubmed: 29156023
Circ Cardiovasc Interv. 2014 Apr;7(2):240-7
pubmed: 24569597
JACC Cardiovasc Imaging. 2019 Jan;12(1):67-80
pubmed: 30448116